select trial semaglutide cardiovascular outcomes non-diabetic 2023 and in Obesity without Diabetes: The Insights into semaglutide cardiovascular research:

Exposure to very low doses over long periods of time can result in various health effects, including an increased risk of certain cancers

That's not healing that's management

The wide range reflects the uncertainty in sublingual bioavailability

The trade-offs trials and community sources flag most consistently are noticeable water retention by week 2, sharp appetite increase, and measurable elevation in fasting blood glucose community sources commonly treat the 8-week and 12-week HbA1c checks as non-negotiable on an extended MK-677 cycle

10.1172/JCI26640

Interestingly, Retatrutide also shows lower nausea rates (28% vs 44%), meaning better results with comparable or better tolerability